Neoprobe appoints Troup to board
Neoprobe, a developer of oncology and cardiovascular surgical and diagnostic products, has appointed Gordon A. Troup to its board of directors.
Troup, who is recently retired as president of Cardinal Health's nuclear pharmacy services (NPS), spent 17 years with Cardinal, including five as president of NPS and four as group president of pharmaceutical distribution and specialty distribution services, according to the Dublin, Ohio-based Neoprobe.
“Troup's business and marketing expertise will provide significant input as we prepare for the commercial launch of Lymphoseek and as we consider development strategies for our portfolio of biomedical products. Troup has been appointed to a board term ending at the Annual Stockholders' Meeting in 2009, when he is expected to stand for election for another term ending in 2012,” said David Bupp, Neoprobe’s president and CEO.
Troup, who is recently retired as president of Cardinal Health's nuclear pharmacy services (NPS), spent 17 years with Cardinal, including five as president of NPS and four as group president of pharmaceutical distribution and specialty distribution services, according to the Dublin, Ohio-based Neoprobe.
“Troup's business and marketing expertise will provide significant input as we prepare for the commercial launch of Lymphoseek and as we consider development strategies for our portfolio of biomedical products. Troup has been appointed to a board term ending at the Annual Stockholders' Meeting in 2009, when he is expected to stand for election for another term ending in 2012,” said David Bupp, Neoprobe’s president and CEO.